Joseph F McGuire1,2,3, John Piacentini3, Adam B Lewin1,2,4, Erin A Brennan2, Tanya K Murphy2,4, Eric A Storch1,2,4,5,6,7. 1. Department of Psychology, University of South Florida, Tampa, Florida. 2. Department of Pediatrics, University of South Florida, Tampa, Florida. 3. Semel Institute of Neuroscience and Human Behavior, University of California Los Angeles, California, Los Angeles. 4. Department of Psychiatry and Behavioral Neurosciences, University of South Florida, Tampa, Florida. 5. Rogers Behavioral Health - Tampa Bay, Tampa, Florida. 6. All Children's Hospital, Johns Hopkins Medicine, Tampa, Florida. 7. Department of Health Policy and Management, University of South Florida, St. Petersburg, Florida.
Abstract
BACKGROUND: Individual randomized controlled trials (RCTs) have demonstrated the efficacy of cognitive behavioral therapy (CBT) and serotonin reuptake inhibitors (SRIs) for the treatment of youth with obsessive-compulsive disorder (OCD). Although meta-analyses have confirmed these results, there has been minimal examination of treatment moderators or an examination of treatment response and symptom/diagnostic remission for these two treatment types. The present report examined the treatment efficacy, treatment response, and symptom/diagnostic remission for youth with OCD receiving either CBT or SRIs relative to comparison conditions, and examined treatment moderators. METHOD: A comprehensive literature search identified 20 RCTs that met inclusion criteria, and produced a sample size of 507 CBT participants and 789 SRI participants. RESULTS: Random effects meta-analyses of CBT trials found large treatment effects for treatment efficacy (g = 1.21), treatment response (relative risk [RR] = 3.93), and symptom/diagnostic remission (RR = 5.40). Greater co-occurring anxiety disorders, therapeutic contact, and lower treatment attrition were associated with greater CBT effects. The number needed to treat (NNT) was three for treatment response and symptom/diagnostic remission. Random effects meta-analyses of SRI trials found a moderate treatment effect for treatment efficacy (g = 0.50), treatment response (RR = 1.80), and symptom/diagnostic remission (RR = 2.06). Greater methodological quality was associated with a lower treatment response for SRI trials. The NNT was five for treatment response and symptom/diagnostic remission. CONCLUSIONS: Findings demonstrate the treatment effects for CBT and SRIs across three important outcome metrics, and provide evidence for moderators of CBT across trials.
BACKGROUND: Individual randomized controlled trials (RCTs) have demonstrated the efficacy of cognitive behavioral therapy (CBT) and serotonin reuptake inhibitors (SRIs) for the treatment of youth with obsessive-compulsive disorder (OCD). Although meta-analyses have confirmed these results, there has been minimal examination of treatment moderators or an examination of treatment response and symptom/diagnostic remission for these two treatment types. The present report examined the treatment efficacy, treatment response, and symptom/diagnostic remission for youth with OCD receiving either CBT or SRIs relative to comparison conditions, and examined treatment moderators. METHOD: A comprehensive literature search identified 20 RCTs that met inclusion criteria, and produced a sample size of 507 CBT participants and 789 SRIparticipants. RESULTS: Random effects meta-analyses of CBT trials found large treatment effects for treatment efficacy (g = 1.21), treatment response (relative risk [RR] = 3.93), and symptom/diagnostic remission (RR = 5.40). Greater co-occurring anxiety disorders, therapeutic contact, and lower treatment attrition were associated with greater CBT effects. The number needed to treat (NNT) was three for treatment response and symptom/diagnostic remission. Random effects meta-analyses of SRI trials found a moderate treatment effect for treatment efficacy (g = 0.50), treatment response (RR = 1.80), and symptom/diagnostic remission (RR = 2.06). Greater methodological quality was associated with a lower treatment response for SRI trials. The NNT was five for treatment response and symptom/diagnostic remission. CONCLUSIONS: Findings demonstrate the treatment effects for CBT and SRIs across three important outcome metrics, and provide evidence for moderators of CBT across trials.
Authors: Jennifer B Freeman; Abbe M Garcia; Lisa Coyne; Chelsea Ale; Amy Przeworski; Michael Himle; Scott Compton; Henrietta L Leonard Journal: J Am Acad Child Adolesc Psychiatry Date: 2008-05 Impact factor: 8.829
Authors: Golda S Ginsburg; Julie Newman Kingery; Kelly L Drake; Marco A Grados Journal: J Am Acad Child Adolesc Psychiatry Date: 2008-08 Impact factor: 8.829
Authors: Joseph O'Neill; John Piacentini; Susanna Chang; Ronald Ly; Tsz M Lai; Casey C Armstrong; Lindsey Bergman; Michelle Rozenman; Tara Peris; Allison Vreeland; Ross Mudgway; Jennifer G Levitt; Noriko Salamon; Stefan Posse; Gerhard S Hellemann; Jeffry R Alger; James T McCracken; Erika L Nurmi Journal: Neuropsychopharmacology Date: 2017-04-04 Impact factor: 7.853
Authors: Joseph F McGuire; Scott P Orr; Joey K-Y Essoe; James T McCracken; Eric A Storch; John Piacentini Journal: Expert Rev Neurother Date: 2016-06-27 Impact factor: 4.618
Authors: Dan J Stein; Daniel L C Costa; Christine Lochner; Euripedes C Miguel; Y C Janardhan Reddy; Roseli G Shavitt; Odile A van den Heuvel; H Blair Simpson Journal: Nat Rev Dis Primers Date: 2019-08-01 Impact factor: 52.329